Aurora Cannabis Inc (NYSE:ACB)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $5.70, but opened at $6.09. Aurora Cannabis shares last traded at $5.81, with a volume of 12,122,540 shares traded.

ACB has been the subject of several research reports. LADENBURG THALM/SH SH initiated coverage on Aurora Cannabis in a research note on Wednesday, July 17th. They issued a “buy” rating and a $9.00 target price for the company. ValuEngine downgraded Aurora Cannabis from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Desjardins initiated coverage on Aurora Cannabis in a research note on Thursday, April 25th. They issued a “buy” rating and a $9.07 target price for the company. Bank of America downgraded Aurora Cannabis from a “buy” rating to a “neutral” rating and set a $7.30 target price for the company. in a research note on Thursday, July 18th. Finally, Piper Jaffray Companies initiated coverage on Aurora Cannabis in a research note on Monday. They issued a “neutral” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $8.23.

The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.98 and a current ratio of 2.37. The company has a 50 day moving average price of $6.87 and a 200 day moving average price of $7.89. The company has a market capitalization of $6.70 billion, a price-to-earnings ratio of 47.25 and a beta of 2.44.

Aurora Cannabis (NYSE:ACB) last issued its earnings results on Tuesday, May 14th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.05). Aurora Cannabis had a negative net margin of 122.65% and a positive return on equity of 1.24%. The firm had revenue of $49.00 million during the quarter, compared to analyst estimates of $50.92 million. Research analysts forecast that Aurora Cannabis Inc will post -0.23 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Moisand Fitzgerald Tamayo LLC bought a new position in Aurora Cannabis in the 1st quarter valued at about $25,000. Financial Management Professionals Inc. lifted its position in Aurora Cannabis by 586.3% in the 1st quarter. Financial Management Professionals Inc. now owns 3,061 shares of the company’s stock valued at $28,000 after acquiring an additional 2,615 shares in the last quarter. Carroll Financial Associates Inc. bought a new position in Aurora Cannabis in the 1st quarter valued at about $27,000. Burt Wealth Advisors lifted its position in Aurora Cannabis by 1,033.3% in the 1st quarter. Burt Wealth Advisors now owns 3,400 shares of the company’s stock valued at $31,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Mackey Komara & Dankovich LLC bought a new position in Aurora Cannabis in the 2nd quarter valued at about $27,000. 9.10% of the stock is currently owned by institutional investors and hedge funds.

Aurora Cannabis Company Profile (NYSE:ACB)

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Article: Bid-Ask Spread

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.